Alectinib vs Ensartinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline

Alectinib · Alecensa

Marketed by Roche and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT02075840 · Phase 3 · completed

Participants were randomly assigned to alectinib or the active comparator crizotinib (152 versus 151), but the trial was open-label rather than double-blind. The primary progression-free survival endpoint was met, with alectinib showing a hazard ratio of 0.47 versus crizotinib (p<0.0001), but the lack of blinding limits the overall evidence strength.

Next expected readout: November 2026 · NCT04302025 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 (From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months)): Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019). (met)

Result source: NCT02838420

Ensartinib · Ensacove

Marketed by Xcovery Holdings and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT02767804 · Phase 3 · active, not recruiting

This was a randomized, phase 3, active-controlled trial with 290 patients comparing ensartinib to crizotinib, using progression-free survival (a hard clinical endpoint) as the primary measure, and the trial met its primary endpoint with a large, statistically significant improvement favoring ensartinib. However, the study was open-label (no blinding of patients or investigators), which limits confidence in outcome assessments despite the use of independent radiology review, so the evidence is graded as solid but not the highest tier.

Next expected readout: February 2027 · NCT05241028 (registry estimate)

Reported efficacy

Progression-free survival (PFS) (36 months): eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001. (met)

Result source: NCT02767804

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlectinibEnsartinib
PFS, median10.9 vs 1.4vs Premetrexed/Docetaxeln 79NCT02604342
5 other results
  • 25.7 vs 10.4 n 152 · Phase 3 · secondary NCT02075840
  • 7.1 vs 1.6 n 72 · Phase 3 · secondary NCT02604342
  • 8.2 600 mg (Fed) · n 87 · Phase 1/2 · secondary NCT01871805
  • 8.4 600 mg (Fed) · n 87 · Phase 1/2 · secondary NCT01871805
  • 8.9 n 138 · Phase 1/2 · secondary NCT01801111
—Trial running · NCT06955325
OS, median81.1 vs 54.2vs Crizotinibn 152NCT02075840
3 other results
—Trial running · NCT06955325
ORR82.9% vs 75.5%vs Crizotinibn 152NCT02075840
9 other results
—Trial running · NCT06955325
Duration of response, median42.3 vs 11.1vs Crizotinibn 126NCT02075840
3 other results
  • 14.9 600 mg (Fed) · n 35 · Phase 1/2 · secondary NCT01871805
  • 13.3 600 mg (Fed) · n 46 · Phase 1/2 · secondary NCT01871805
  • 15.2 n 62 · Phase 1/2 · secondary NCT01801111
—Trial running · NCT06955325

PFS, median

Alectinib
10.9 vs 1.4vs Premetrexed/Docetaxeln 79NCT02604342
5 other results
  • 25.7 vs 10.4 n 152 · Phase 3 · secondary NCT02075840
  • 7.1 vs 1.6 n 72 · Phase 3 · secondary NCT02604342
  • 8.2 600 mg (Fed) · n 87 · Phase 1/2 · secondary NCT01871805
  • 8.4 600 mg (Fed) · n 87 · Phase 1/2 · secondary NCT01871805
  • 8.9 n 138 · Phase 1/2 · secondary NCT01801111
Ensartinib
—Trial running · NCT06955325

OS, median

Alectinib
81.1 vs 54.2vs Crizotinibn 152NCT02075840
3 other results
Ensartinib
—Trial running · NCT06955325

ORR

Alectinib
82.9% vs 75.5%vs Crizotinibn 152NCT02075840
9 other results
Ensartinib
—Trial running · NCT06955325

Duration of response, median

Alectinib
42.3 vs 11.1vs Crizotinibn 126NCT02075840
3 other results
  • 14.9 600 mg (Fed) · n 35 · Phase 1/2 · secondary NCT01871805
  • 13.3 600 mg (Fed) · n 46 · Phase 1/2 · secondary NCT01871805
  • 15.2 n 62 · Phase 1/2 · secondary NCT01801111
Ensartinib
—Trial running · NCT06955325
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Alectinib: 4 of 4 rows · Ensartinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlectinibEnsartinib
Dropout rate
n/a: no completion milestonea
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
n/a: no completion milestone
NCT02838420 · Phase 3 · monotherapy
54.4%
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestone
NCT01801111 · Phase 1/2
—600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
0%225 mgb
NCT01625234 · Phase 1/2
show 7 more results
0%225 mg
NCT01625234 · Phase 1/2
0%250 mg
NCT01625234 · Phase 1/2
0%200 mg
NCT01625234 · Phase 1/2
0%100 mg
NCT01625234 · Phase 1/2
0%50 mg
NCT01625234 · Phase 1/2
0%25 mg
NCT01625234 · Phase 1/2
n/a: no completion milestone200 mg
NCT02898116 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
0%a
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
—
NCT02838420 · Phase 3 · monotherapy
—
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
8.7%
NCT01801111 · Phase 1/2
—600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
—225 mgb
NCT01625234 · Phase 1/2
show 7 more results
—225 mg
NCT01625234 · Phase 1/2
—250 mg
NCT01625234 · Phase 1/2
—200 mg
NCT01625234 · Phase 1/2
—100 mg
NCT01625234 · Phase 1/2
—50 mg
NCT01625234 · Phase 1/2
—25 mg
NCT01625234 · Phase 1/2
50%200 mg
NCT02898116 · Phase 1/2 · registry result, not featured evidence
Serious AEs
46.1%a
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
15.2%
NCT02838420 · Phase 3 · monotherapy
26%
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
28.3%
NCT01801111 · Phase 1/2
24.1%600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
50%225 mgb
NCT01625234 · Phase 1/2
show 7 more results
43.6%225 mg
NCT01625234 · Phase 1/2
50%250 mg
NCT01625234 · Phase 1/2
54.5%200 mg
NCT01625234 · Phase 1/2
40%100 mg
NCT01625234 · Phase 1/2
33.3%50 mg
NCT01625234 · Phase 1/2
25%25 mg
NCT01625234 · Phase 1/2
50%200 mg
NCT02898116 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
a
constipation 40.1%
anaemia 27.6%
blood bilirubin increased 24.3%
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
aspartate aminotransferase increased 52%
blood bilirubin increased 48.8%
blood creatine phosphokinase increased 44%
NCT02838420 · Phase 3 · monotherapy
constipation 20.8%
anaemia 15.6%
myalgia 14.3%
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
constipation 38.4%
fatigue 31.2%
oedema peripheral 30.4%
NCT01801111 · Phase 1/2
600 mg (Fed)
fatigue 41.4%
constipation 39.1%
headache 28.7%
NCT01871805 · Phase 1/2 · registry result, not featured evidence
225 mgb
gastrointestinal disorders 25%
nausea 25%
vomiting 25%
NCT01625234 · Phase 1/2
show 7 more results
225 mg
gastrointestinal disorders 60.6%
nausea 38.3%
vomiting 25.5%
NCT01625234 · Phase 1/2
250 mg
gastrointestinal disorders 50%
vomiting 50%
nausea 30%
NCT01625234 · Phase 1/2
200 mg
gastrointestinal disorders 54.5%
nausea 45.5%
vomiting 36.4%
NCT01625234 · Phase 1/2
100 mg
gastrointestinal disorders 40%
anaemia 20%
blood and lymphatic 20%
NCT01625234 · Phase 1/2
50 mg
gastrointestinal disorders 33.3%
nausea 33.3%
vomiting 33.3%
NCT01625234 · Phase 1/2
25 mg
anaemia 25%
blood and lymphatic 25%
blood creatinine increased 25%
NCT01625234 · Phase 1/2
200 mg
hypoalbuminaemia 100%
anaemia 50%
arthralgia 50%
NCT02898116 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 3 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alectinib

PFS NA vs 11.1 Crizotinib months
time to event · months
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
25.7 vs 10.4 Crizotinib months
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
NA vs 11.1 Crizotinib months
NCT02838420 · Phase 3 · monotherapy
10.9 vs 1.4 Premetrexed/Docetaxel months
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
7.1 vs 1.6 Premetrexed/Docetaxel months
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
CNS Progression 11.8% (n=152) vs 45% (n=151) Crizotinib
responder rate · % of participants
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
10.5% (n=152) vs 35.8% (n=151) Crizotinib
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
ORR 82.9% (n=152) vs 75.5% (n=151) Crizotinib
responder rate · % of participants
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
48.1% (n=52) vs 0% (n=28) Premetrexed/Docetaxel
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Duration of Response 42.3 vs 11.1 Crizotinib months
time to event · months
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Overall Survival 81.1 vs 54.2 Crizotinib months
time to event · months
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
27.8 vs NA Premetrexed/Docetaxel months
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
CNS ORR 59.4% (n=152) vs 25.9% (n=151) Crizotinib
responder rate · % of participants
Measurable and non-measurable CNS lesions
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
CNS DOR 17.3 vs 5.5 Crizotinib months
absolute value · months
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration C30 Dyspnoea NA vs NA Crizotinib months
time to event · months
Dyspnea
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration LC13 Cough NA vs NA Crizotinib months
time to event · months
Coughing
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration Dyspnea 22.8 vs NA Crizotinib months
time to event · months
Dyspnea
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration LC13 Chest Pain NA vs NA Crizotinib months
time to event · months
Pain in chest
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration Composite Symptoms 12.7 vs 21 Crizotinib months
time to event · months
Composite score (c, p in c, d)
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3

+ 635 further endpoints in the CSV export.

Ensartinib

ORR 42% (n=81) @ 78wk225 mg
event count · % of participants
No placebo or comparator arm
NCT01625234 · Phase 1/2 · converted to % from 34 participants as posted
Stable Disease 0% (n=2)200 mg
event count · % of participants
No placebo or comparator arm
SD
NCT02898116 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 Participants as posted
Progressive Disease 100% (n=2)200 mg
event count · % of participants
No placebo or comparator arm
PD
NCT02898116 · Phase 1/2 · registry result, not featured evidence · converted to % from 2 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alectinib's landscape · Ensartinib's landscape